EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Optimizing Ki-67 and E-Cadherin Thresholds for Improved Grade and Stage Classification in Urothelial Bladder Cancer

Stefan Harsanyi iD, Zuzana Varchulova Novakova, Lucia Neuschlova, Stefan Galbavy, Lubos Danisovic iD, Stanislav Ziaran, Katarina Bevizova

Journal of Clinical Medicine · 02.01.2026 · 15 (1) · 338

DOI: 10.3390/jcm15010338 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 02.01.2026. Verfasst von Stefan Harsanyi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medical Biology, Genetics and Clinical Genetics, Faculty of Medicine, Comenius University in Bratislava, 811 08 Bratislava, Slovakia. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Operational Program Integrated Infrastructure.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Bladder cancer exhibits substantial heterogeneity, and accurate discrimination between non-muscle-invasive (NMIBC) and muscle-invasive disease (MIBC), as well as between low-grade (LG) and high-grade (HG) tumors, remains essential for appropriate clinical management. Established immunohistochemical (IHC) markers, such as p53, Ki-67, and E-cadherin, could be used in a new setting, but standardized cut-off values and their combined predictive value remain unclear. This study aimed to identify optimal cut-offs for these markers and to evaluate whether biomarker combinations enhance the discrimination of tumor grade and stage.

Methods

A retrospective dataset of 568 cases of bladder cancer was analyzed. For each case, the expression of p53, Ki-67, and E-cadherin was quantified, and tumors were classified as NMIBC or MIBC, and as LG or HG. ROC-based cut-off selection was performed using Youden’s J criterion with 10-fold stratified cross-validation. E-cadherin was modelled using an inverted scale to reflect biological loss. Logistic regression models were used to evaluate the discriminatory performance of single markers, two-marker combinations, and a three-marker model. Cross-validated AUC values and optimal thresholds were reported.

Results

Ki-67 showed the strongest single-marker performance for predicting both MIBC (AUC 0.842) and HG disease (AUC 0.813), with optimal cut-offs of ≥40% and ≥30%, respectively. p53 demonstrated moderate discrimination (AUC 0.778 for MIBC and 0.776 for HG), while E-cadherin, evaluated on an inverted scale, showed acceptable performance (AUC 0.746 for MIBC; 0.780 for HG). Combining markers yielded modest improvements, with the best performance observed for Ki-67 + E-cadherin (AUCs of 0.851 for MIBC and 0.838 for HG).

Conclusions

Ki-67 is the most effective single biomarker for distinguishing invasive and HG bladder cancer, while E-cadherin provides complementary value. A two-marker panel combining Ki-67 and E-cadherin, using appropriate cut-offs, offers the highest overall performance and may serve as a practical tool for enhanced pathological stratification.

Schlagwörter

Stichwörter der Autor:innen

E-cadherinKi-67MIBCROC analysisbiomarkersbladder cancercut-off analysisp53tumor grade

Autor:innen und Institutionen

  • Institute of Medical Biology, Genetics and Clinical Genetics, Faculty of Medicine, Comenius University in Bratislava, 811 08 Bratislava, Slovakia.
  • Institute of Forensic Medicine, Faculty of Medicine, Comenius University in Bratislava, 811 08 Bratislava, Slovakia.
  • Department of Urology, Faculty of Medicine, Comenius University in Bratislava, 826 06 Bratislava, Slovakia.
  • Institute of Anatomy, Faculty of Medicine, Comenius University in Bratislava, 811 08 Bratislava, Slovakia.

ORCID-Profile: Stefan Harsanyi, Lubos Danisovic

Förderung

  • Operational Program Integrated Infrastructure

Zitieren

APA

Harsanyi, S., Novakova, Z. V., Neuschlova, L., Galbavy, S., Danisovic, L., Ziaran, S., & Bevizova, K. (2026). Optimizing Ki-67 and E-Cadherin Thresholds for Improved Grade and Stage Classification in Urothelial Bladder Cancer. Journal of Clinical Medicine, 15(1), 338. https://doi.org/10.3390/jcm15010338

Vancouver

Harsanyi S, Novakova ZV, Neuschlova L, Galbavy S, Danisovic L, Ziaran S, et al. Optimizing Ki-67 and E-Cadherin Thresholds for Improved Grade and Stage Classification in Urothelial Bladder Cancer. Journal of Clinical Medicine. 2026;15(1):338. doi:10.3390/jcm15010338

BibTeX
@article{Harsanyi2026,
  author = {Harsanyi, Stefan and Novakova, Zuzana Varchulova and Neuschlova, Lucia and Galbavy, Stefan and Danisovic, Lubos and Ziaran, Stanislav and Bevizova, Katarina},
  title = {Optimizing Ki-67 and E-Cadherin Thresholds for Improved Grade and Stage Classification in Urothelial Bladder Cancer},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {1},
  pages = {338},
  doi = {10.3390/jcm15010338}
}
Kostenlos starten →